Navigation Links
Epeius Biotechnologies Awarded U.S. Patent for Targeted Injectable Gene Delivery In Vivo
Date:3/25/2008

SAN MARINO, Calif., March 25 /PRNewswire/ -- Epeius Biotechnologies Corporation announced today the issue of U.S. Patent No. 7,347,998 for Targeted Gene Delivery in vivo. This patent provides additional intellectual property protection for the platform of highly advanced biotechnologies embodied in the company's leading anti-cancer agent, Rexin-G. Administered clinically by simple intravenous infusion, the Epeius tumor-targeted gene delivery system enables Rexin-G to seek out and accumulate selectively in cancerous tissues and remote metastatic tumor nodules that have spread throughout the body. Rexin-G delivers it tumor-killing payload precisely where it is needed most, by targeting cancer from the inside.

*(LOGO: Send2Press.com/mediaboom/08-0325-Epeius_72dpi.jpg)

Rexin-G demonstrates profound single agent efficacy in a broad spectrum of chemotherapy refractory cancers, including pancreatic cancer, breast cancer, colon cancer, squamous cell carcinoma of larynx, uterine cancer, gastric cancer, malignant melanoma, validating Epeius Biotechnologies' in vivo targeted gene delivery platform [Int'l J Oncol, 2006, 2007].

The response rates seen with Rexin-G are unmatched by any other tumor- targeted gene delivery system. The U.S. FDA has granted Orphan Drug Status to Rexin-G based on its performance as a single therapeutic agent in treating chemotherapy refractory pancreatic cancer. Based on its exemplary record of safety and efficacy as an anti-cancer agent in a broad spectrum of chemo- resistant tumors, Rexin-G received accelerated approval for the treatment of all solid tumors by the Philippine BFAD, leading to its registration. Currently, Rexin-G is being tested as a single therapeutic agent in three separate U.S. Phase I/II Trials for recurrent or metastatic cancers of the breast or pancreas and for bone and soft tissue sarcoma respectively. Additionally, a Phase II Registration Protocol is underway for chemo-resistant osteosarcoma in Los
'/>"/>

SOURCE Epeius Biotechnologies Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Epeius Biotechnologies Leads With Keynote Address on the Advent of Pathotropic Medicine for Cancer at the Global Pharma R&D Summit Conference in Boston MA
2. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
3. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
4. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
5. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Completion of $2,277,000 Equity Financing
6. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Appointment of Mark C. Mirken as its President and Chief Operating Officer
7. Amyris Biotechnologies Announces $70 Million Series B Round
8. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
9. Maven Biotechnologies, LLC to Present at BIOCOM Investor Conference
10. Millennium Biotechnologies, Inc. Launches SURGEX(TM) the First Scientifically Validated Sports Nutritional Product Created from the Medical Markets
11. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aug. 21, 2014  Decision Resources Group finds ... and Mexico ... several newly approved agents, the anticipated label extension ... the launch of emerging biologics will substantially increase ... the emerging IL-5 inhibitors will introduce a new dynamic ...
(Date:8/21/2014)... KONG , Aug. 21, 2014  China Cord Blood ... announced its plan to release financial results for the ... 28, 2014, after market close in the US.  ... at 8:00 a.m. ET on Friday, August 29, 2014 ... overview of the Company,s recent developments, followed by a ...
(Date:8/21/2014)... Ontotext S4 , The Self Service ... Now the same enterprise hardened text mining, Linked ... data is available to start-ups and mid-size businesses at ... that do not have resources to evaluate and prototype ... since there is no need for on premise hardware ...
(Date:8/21/2014)... August 21, 2014 On Wednesday of last ... to use Redox Signaling molecules, became available for purchase in ... , "The way that RENU 28 works is, if you ... down of the rate of cellular renewal within your body. ... increasing of that rate of cellular renewal. What RENU 28 ...
Breaking Biology Technology:Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4RENU 28 Skin Care Now Available in Australia and New Zealand 2
... Inc.,(Nasdaq: NGSX ), a biopharmaceutical company focused ... today that,Anthony DiTonno, President and Chief Executive Officer, ... Healthcare Unplugged Conference in New,York City on Tuesday, ... Financial Officer, will be available to respond to ...
... BETHESDA, Md., Sept. 2 Micromet, Inc.,(Nasdaq: ... company,developing novel, proprietary antibodies for the treatment of ... of,Barclay A. Phillips as Senior Vice President and ... member of the Company,s board of directors,since 2000, ...
... /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) ... Administration (FDA) review, the Company is initiating ... administration of REOLYSIN(R) in,combination with paclitaxel and ... (NSCLC) with K-RAS or EGFR-activated tumours. The ...
Cached Biology Technology:NeurogesX to Present at Morgan Stanley Global Healthcare Unplugged Conference 2NeurogesX to Present at Morgan Stanley Global Healthcare Unplugged Conference 3Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer 2Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer 3Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer 4Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours 2Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours 3Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours 4
(Date:8/22/2014)... rhino reproduction in Europe highlights how hormone analysis ... Researchers from Chester Zoo, The University of Manchester ... six-year study which encompassed 90% of European population ... the research as part of her PhD at ... black rhinoceros breed well in captivity, not all ...
(Date:8/22/2014)... be able to purchase fuel cell cars from Toyota ... of the cars will run on hydrogen made from ... warming. , Now scientists at Stanford University have developed ... battery to produce hydrogen by water electrolysis. The ... split liquid water into hydrogen and oxygen gas. Unlike ...
(Date:8/21/2014)... a significant reduction in smog-producing toxins in past ... A new study shows that while the Greater ... the toxins that contribute to smog, the city ... air pollution., Smog, which can cause or aggravate ... bronchitis, is produced by a set of complex ...
Breaking Biology News(10 mins):Hormone analysis helps identify horny rhinos 2Stanford scientists develop a water splitter that runs on an ordinary AAA battery 2Stanford scientists develop a water splitter that runs on an ordinary AAA battery 3Despite a significant reduction in smog-producing toxins, the Greater Toronto Area still violates Canada's standards for ozone air pollution 2
... been identified in sediment-laden marine environments, conditions previously believed to ... that Middle Reef part of Australia,s iconic Great Barrier ... in areas with lower levels of sediment stress. Led ... team of scientists is published today (1 August 2012) in ...
... from the Wildlife Conservation Society (WCS) and the National Research ... called an imperial cormorant with a small camera, then watched ... in 40 seconds, feeding on the ocean floor for 80 ... to the surface 40 seconds later. This is the ...
... appendages that plague many people in the winter and an ... for singles and couples alike. In a new study, scientists ... Nationwide Children,s Hospital have identified a biological mechanism that may ... of molecules and receptors on smooth muscle cells that line ...
Cached Biology News:Coral reef thriving in sediment-laden waters 2Are cold feet plaguing your relationship? 2Are cold feet plaguing your relationship? 3